#abemaciclib
LightNews LightNews
untidymusic.com
Also Abemaciclib side effects can be increased.
pjadams1994.bsky.social PJ Adams @pjadams1994.bsky.social · Jun 25
Seen this doing the rounds on Instagram but not so much on here ❤️
Anti-depressants heat warning If you/someone you know are taking antidepressants such as Sertraline, Citalopram, Fluoxetine, Duloxetine, Mirtazapine or other SSRIs/SNRIs - BE AWARE: these medications can make it more likely you could struggle from heat stroke. Stay hydrated, avoid direct sun when possible, and wear sun cream! Please share to spread the word.
June 25, 2026 at 11:14 AM
nejm.org
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX

#MedSky #SABCS24
Kaplan–Meier estimates of progression-free survival among all 426 patients in the imlunestrant–abemaciclib and imlunestrant groups who had undergone randomization concurrently.
December 11, 2024 at 2:08 PM
oncodaily.bsky.social
EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EMBER3 #ESMOBreast25 #BreastCancer #Imlunestrant #Abemaciclib
EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer - OncoDaily
ESMO Breast 2025: Imlunestrant + abemaciclib shows PFS benefit in CDK4/6i-pretreated ER+/HER2- advanced breast cancer, per EMBER-3 data.
oncodaily.com
May 15, 2025 at 10:34 PM
onclive.bsky.social
🎯 Abemaciclib has delivered the first positive phase 3 trial result in advanced dedifferentiated liposarcoma, marking a significant breakthrough in a disease where effective systemic treatment options have long been limited. 📊🧬
Read more here: www.onclive.com/view/abemaci...
#oncology #ASCO26
Abemaciclib Produces First Positive Phase 3 Trial Result in Dedifferentiated Liposarcoma | OncLive
Abemaciclib markedly improved PFS vs placebo in patients with advanced dedifferentiated liposarcoma.
www.onclive.com
May 31, 2026 at 11:27 PM
oncodaily.bsky.social
Press Release: Verzenio (Abemaciclib) Increases Overall Survival in High-Risk HR+, HER2- Early BC.

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Verzenio #Abemaciclib #BC #BreastCancer
Abemaciclib Boosts Survival in High-Risk HR+, HER2- BC
Verzenio® (Abemaciclib) improves overall survival in high-risk HR+, HER2- early BC. MonarchE trial results and its impact on treatment.
oncodaily.com
August 30, 2025 at 12:48 AM
drsarahsammons.bsky.social
Great work showing half of patients with metastatic relapse after adjuvant abemaciclib have loss of estrogen expression.

Biopsy remains critical.

#sabcs24 @oncbrothers.bsky.social
ccortimd.bsky.social Chiara Corti, MD @ccortimd.bsky.social · Dec 13
Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊
#SABCS2024 @sabcs.bsky.social
December 13, 2024 at 2:19 PM
oncodaily.bsky.social
Imlunestrant + abemaciclib likely to become a new 2L treatment option for HR+/HER2- Metastatic breast cancer

@ptarantinomd.bsky.social
@breastcancerdoc.bsky.social

oncodaily.com/blog/imlunes...

#Cancer #Imlunestrant #OncoDaily #Oncology #Medicine #Health
Imlunestrant + abemaciclib likely to become a new 2L treatment option for HR+/HER2- Metastatic breast cancer - OncoDaily
Imlunestrant + abemaciclib likely to become a new 2L treatment option for HR+/HER2- Metastatic breast cancer / cancer, Imlunestrant, Komal Jhaveri, OncoDaily,
oncodaily.com
December 13, 2024 at 6:13 PM
drsgraff.bsky.social
Now online in JCO #postMonarch

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial
PURPOSECyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor re...
ascopubs.org
December 22, 2024 at 10:31 PM
elisaagostinetto.bsky.social
While waiting for the very much awaited presentation at #SABCS24, results of EMBER-3 are out in @NEJM‼️

Imlunestrant–abemaciclib significantly ⬆️ PFS as compared with imlunestrant, regardless of ESR1-mutation status

@oncoalert.bsky.social

www.nejm.org/doi/full/10....
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer | NEJM
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (E...
www.nejm.org
December 11, 2024 at 2:02 PM
dfcibreastonc.bsky.social
📢 Just published! A phase II study of #abemaciclib for patients with #retinoblastoma-positive, triple-negative #metastatic breast cancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39908010/
@drtimothyerick.bsky.social @nlinmd.bsky.social
@stolaney1.bsky.social
February 7, 2025 at 7:40 PM
drsgraff.bsky.social
“It is impressive that the combination [of imlunestrant and abemaciclib] seems to tower above the rest” — @DrHalBurstein
sharing his self-proclaimed dreaded cross trial comparison (students, biostatisticians: *avert your eyes*) #SABCS24 @oncoalert.bsky.social
December 11, 2024 at 3:45 PM
nejm.org
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX

#MedSky #Oncology
The New England Journal of Medicine Imlunestrant with or without Abemaciclib in Advanced Breast Cancer A Research Summary based on Jhaveri KL et al. | 10.1056/NEJMoa2410858 | Published on December 11, 2024 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
April 5, 2025 at 4:02 PM
re-mcgee.bsky.social
I have come back to messages asking how I am.
It has been hard, but I am about to finish abemaciclib which will make life much easier. Other medication changes have left me feeling tired and sick a lot & so there has been no gardening.
I am teaching myself to crochet though. This is 2 weeks in.
January 11, 2026 at 4:25 PM
castltrastondrs.medsky.network
#Medsky #oncosky #pharmasky Among patients with ER+ve #Breastcancer, HER2-ve advanced
BC #imlunestrant led to significantly longer progression-free survival vs standard Tx with ESR1 mutations & #Imlunestrant - #abemaciclib improved progression-free survival vs #imlunestrant alone .
nejm.org NEJM.org @nejm.org · Apr 5
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX

#MedSky #Oncology
The New England Journal of Medicine Imlunestrant with or without Abemaciclib in Advanced Breast Cancer A Research Summary based on Jhaveri KL et al. | 10.1056/NEJMoa2410858 | Published on December 11, 2024 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
April 5, 2025 at 4:14 PM
mskcancercenter.bsky.social
🚨 The FDA has approved imlunestrant (Inluriyo™) in combination with abemaciclib (Verzenio®) for patients with ER-positive, HER2-negative advanced #breastcancer with an ESR1 gene mutation who were previously treated with hormone therapy.
September 21, 2026 at 5:36 PM
drsgraff.bsky.social
EMBER3 shows benefit of imlunestrant in patients with HR+ MBC and mESR1
and for the combination of imlunestrant and Abemaciclib for all patients, regardless of ESR1 status #SABCS24
@sabcs.bsky.social @breastcancerdoc.bsky.social @oncoalert.bsky.social
December 11, 2024 at 3:34 PM
stage4kelly.bsky.social
Another up and coming (ie, may well be fda approved in the near future) agent is imlunestrant, as monotherapy or in combo with abemaciclib #SABCS24 @breastcancerdoc.bsky.social
December 11, 2024 at 3:44 PM
danafarbernews.bsky.social
Research led by @danafarbernews.bsky.social’s Dr. Adrienne Waks shows combination therapy of avutometinib, abemaciclib and fulvestrant is active, safe in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer, reports @onclive.bsky.social from #AACR25. bit.ly/3YTUmni
Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer
Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.
bit.ly
April 30, 2025 at 5:30 PM
zoezhang.bsky.social
10/20 #TumorBoardTuesday
What would you select as next line of therapy?
1. Abemaciclib+fulvestrant
2. Elacestrant
3. Evaluate for clinical trials involving novel SERDs
@dr-rshatsky.bsky.social
January 15, 2025 at 1:28 AM
stage4kelly.bsky.social
Love advocate and friend living with MBC Victoria Goldberg making the point that in the case of abemaciclib NOBODY is on the MTD!! #SABCS24 #bcsm
December 10, 2024 at 6:31 PM
elisabettabonzano.bsky.social
📌 EMBER-3 Trial: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy & Combined with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine Therapy (ET) presented by @jhaveri_komal 👏🏻
#SABCS24 #day2 @oncoalert.bsky.social
December 11, 2024 at 3:37 PM
thailandmedical.bsky.social
Breakthrough Breast Cancer Drug Abemaciclib Boosts Survival

www.thailandmedical.news/news/breakth...
Breakthrough Breast Cancer Drug Abemaciclib Boosts Survival - Thailand Medical News
www.thailandmedical.news
October 24, 2025 at 10:50 AM
aftimosp.bsky.social
Masterful discussion by Dr Burstein of the results of the EMBER-3 study at #SABCS24 :
🔸Imlunestrant + Abemaciclib breaking out of the ESR1m box
🔸”Non academic” cross-trial comparison

#bcsm @oncoalert.bsky.social
December 11, 2024 at 3:59 PM
clin-pharmacology.bsky.social
Our new paper in Clinical Pharmacology & Therapeutics: abemaciclib raises creatinine while cystatin C falls, but half of our patients already met the discrepancy criterion at baseline. Measure cystatin C before starting, not after the creatinine rises.

ascpt.onlinelibrary.wiley.com/doi/10.1002/...
Creatinine–Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib
Abemaciclib increases serum creatinine by inhibiting renal tubular transporters rather than reducing true glomerular filtration rate, a phenomenon known as pseudo-acute kidney injury. Creatinine–cyst...
ascpt.onlinelibrary.wiley.com
September 23, 2026 at 11:45 PM
kirach.bsky.social
Die Studie will herausfinden, ob ein Medikament, das bei metastasiertem Brustkrebs eingesetzt wird, auch das Rezidiv-Risiko senken kann. Das Zeug heißt Abemaciclib & bremst Vermehrung und Wachstum von bestimmten Zellen.
& ich bin in dem Arm der Studie, die das Medikament tatsächlich bekommt, yay!
July 11, 2024 at 9:38 AM